Extracellular Chromatin Triggers Release of Soluble CEACAM8 Upon Activation of Neutrophils.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 14 12 2018
accepted: 28 05 2019
entrez: 2 7 2019
pubmed: 2 7 2019
medline: 11 11 2020
Statut: epublish

Résumé

Increased concentrations of extracellular chromatin are observed in cancer, sepsis, and inflammatory autoimmune diseases like systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). In SLE and RA, extracellular chromatin may behave as a danger-associated molecular pattern (DAMP). Polymorphonuclear neutrophils (PMN) are described as typical pro-inflammatory cells but possess also immunoregulatory properties. They are activated in SLE and RA but surprisingly remain moderately studied in these diseases, and especially the disease-associated stimuli triggering PMN activation are still not completely characterized. PMN express plasma membrane carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 8 (CD66b) and secrete a soluble form of CEACAM8 after activation. Soluble CEACAM8 has in turn immunoregulatory functions. However, few natural stimuli inducing soluble CEACAM8 secretion by PMN have been identified. Here we demonstrate for the first time that extracellular chromatin triggers secretion of soluble CEACAM8 by primary human PMN. Priming of PMN was not required. Secretion was associated with activation of PMN. Similar induction of soluble CEACAM8 release was observed with purified mono-nucleosomes as well as long chromatin fragments and occurred in a time-dependent and concentration-dependent manner. Results indicate that chromatin induces both neo-synthesis of soluble CEACAM8 and release of soluble CEACAM8 through degranulation. In addition, we report the presence of soluble CEACAM8 at high concentration in the synovial fluid of RA patients. Thus, we describe here a novel mechanism by which a natural DAMP, with inflammatory properties in SLE and RA, induces soluble CEACAM8 secretion by activated PMN with potential immunoregulatory consequences on other immune cells, including PMN.

Identifiants

pubmed: 31258530
doi: 10.3389/fimmu.2019.01346
pmc: PMC6587075
doi:

Substances chimiques

Alarmins 0
Antigens, CD 0
CEACAM6 protein, human 0
CEACAM8 protein, human 0
Cell Adhesion Molecules 0
Chromatin 0
GPI-Linked Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1346

Références

J Leukoc Biol. 1999 Sep;66(3):429-36
pubmed: 10496313
Arthritis Rheum. 2000 Jan;43(1):76-84
pubmed: 10643702
J Immunol. 2002 May 15;168(10):5139-46
pubmed: 11994468
Arthritis Rheum. 2003 Oct;48(10):2796-806
pubmed: 14558085
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Br J Haematol. 2004 Jun;125(5):666-73
pubmed: 15147383
J Immunol. 2005 Mar 15;174(6):3326-34
pubmed: 15749864
Ann Rheum Dis. 2005 Oct;64(10):1436-42
pubmed: 15778239
Nat Immunol. 2006 Jan;7(1):40-8
pubmed: 16286919
J Immunol. 2006 Dec 1;177(11):7740-9
pubmed: 17114445
Arthritis Res Ther. 2007;9(2):R25
pubmed: 17341304
Nat Immunol. 2008 Nov;9(11):1270-8
pubmed: 18836450
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15867-72
pubmed: 19720992
Blood. 2010 Jan 14;115(2):335-43
pubmed: 19890092
Immunity. 2009 Nov 20;31(5):761-71
pubmed: 19913447
Immunology. 2010 Jan;129(1):55-61
pubmed: 20050330
Blood. 2010 Jul 29;116(4):625-7
pubmed: 20410504
Eur J Immunol. 2011 Mar;41(3):669-81
pubmed: 21287547
Nat Immunol. 2011 Dec 25;13(2):170-80
pubmed: 22197976
J Immunol. 2012 Nov 15;189(10):4806-15
pubmed: 23053514
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19386-91
pubmed: 23132945
J Clin Immunol. 2013 Jul;33(5):925-37
pubmed: 23479181
J Biol Chem. 2013 May 10;288(19):13534-50
pubmed: 23553627
Eur J Immunol. 2013 Aug;43(8):2101-13
pubmed: 23686399
Ann Rheum Dis. 2014 Dec;73(12):2199-207
pubmed: 24013727
PLoS One. 2014 Apr 17;9(4):e94106
pubmed: 24743304
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E546-55
pubmed: 25624468
J Autoimmun. 2019 Mar;98:122-131
pubmed: 30704942
Cancers (Basel). 2019 Mar 13;11(3):null
pubmed: 30871206
Immunol Invest. 1995 Aug;24(5):829-43
pubmed: 8543346
Arthritis Rheum. 1997 Apr;40(4):648-54
pubmed: 9125246
J Mol Biol. 1997 Oct 17;273(1):52-60
pubmed: 9367745
Arthritis Rheum. 1997 Dec;40(12):2217-25
pubmed: 9416860

Auteurs

Matthieu Ribon (M)

Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France.
Inserm UMR 1125, Li2P, Bobigny, France.

Julie Mussard (J)

Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France.
Inserm UMR 1125, Li2P, Bobigny, France.

Luca Semerano (L)

Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France.
Inserm UMR 1125, Li2P, Bobigny, France.
Rheumatology Department, Avicenne Hospital, AP-HP, Bobigny, France.

Bernhard B Singer (BB)

Institute of Anatomy, University Hospital, University Duisburg-Essen, Essen, Germany.

Patrice Decker (P)

Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France.
Inserm UMR 1125, Li2P, Bobigny, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH